Latest News

Written by Ι Stock Market Media — October 16, 2019

NEW YORK, NY, Oct. 16, 2019 — PharmaCyte Biotech (OTCQB: PMCB) has now moved one step closer to submitting an Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA) to request a clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) in the United States.  The company has successfully completed the first of two manufacturing runs to produce the clinical trial product (Cell-in-a-Box^® capsules) it needs for ...

Written by Ι Stock Market Media — August 26, 2019

New York, NY — Tech Central, Inc. (OTC Markets: TCHC) entered the CBD market this year (2019) with an aggressive approach that not only included launching its own CBD products, but also includes helping burgeoning businesses build their exclusive CBD brand in the industry as well.

In just a few short months, the company has announced the development of its “CBD Affiliate Marketer” app, launched its “Better Mind CBD” line ...

Written by Ι Stock Market Media — March 27, 2019

Cyber Security 1 (OTCQX: CYBNY) (Nasdaq First North: CYB1), a leading international cyber security firm that provides cyber resilience solutions to an ever-growing list of clients globally, enjoyed record revenue growth in 2018.  The company’s recent financial report highlights what was an impressive 2018 for Cyber Security 1 (CYBER1).  The report states that CYBER1 set records with back-to-back quarters of total quarterly revenue growth and year-over-year total annual revenue growth.

After a ...

Written by Ι Stock Market Media — February 22, 2019

Make no mistake about it the growth of the worldwide legal cannabis industry is exploding exponentially. One key driver behind this explosion is the many nations that have been decriminalizing cannabis and legalizing the use of marijuana for both medical and recreational uses. With more new countries dotting the legal cannabis landscape seemingly every day, ICC International Cannabis Corp. or “ICC” (OTC Markets: WLDCF) (CSE: WRLD.U) (FWB: 8K51) is capitalizing on the ...

Written by Ι Stock Market Media — February 4, 2019

Clinical stage biotechnology company PharmaCyte Biotech (OTCQB: PMCB) is now closer than ever to reaching what would be a monumental milestone in the company’s history. Years of patience from PharmaCyte’s shareholders has now likely been whittled down to what should now be just months, and with the condensed timeline, the company is this close to what will be a landmark event—an “open” or approved Investigational New Drug application (IND) with the U.S. ...

Written by Ι Stock Market Media — January 23, 2019

“I am excited about this new approach that has the potential to change the way solid tumors are treated far beyond tumors in the pancreas.”

NEW YORK, NY – With PharmaCyte Biotech, Inc.’s (OTCQB: PMCB) naming of Medpace, Inc., a global full-service clinical contract research organization (CRO) to conduct its clinical trial in locally advanced, inoperable pancreatic cancer (LAPC), and with the recent news that the live cells necessary for that clinical trial ...